Overview

BIIB033 In Acute Optic Neuritis (AON)

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with their first episode of unilateral acute optic neuritis (AON). The secondary objective of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of BIIB033 in this study population.
Phase:
Phase 2
Details
Lead Sponsor:
Biogen